In a landmark decision, the Supreme Court of India has resolved the long-standing Sterling Biotech case, achieving a total recovery of approximately ₹9,800 crore. This amount significantly exceeds the initial claim of ₹5,383 crore made by the Central Bureau of Investigation against businessman Nitin J. Sandesara and his group. Throughout the proceedings, the Sandesara group repaid ₹3,507 crore directly to the lending consortium, with an additional ₹1,192 crore recovered through liquidation processes. The apex court's compliance order, issued on December 17, 2025, confirmed that the total deposited amount surpassed ₹5,100 crore. Following the recovery, the court ordered the closure of all related proceedings, effectively ending investigations by agencies such as the Enforcement Directorate and the Serious Fraud Investigation Office. The Supreme Court also expedited remaining regulatory aspects involving the Securities and Exchange Board of India, ensuring a swift conclusion to the case. The final compliance was achieved with a demand draft deposit on April 13, 2026, completing all formalities under the settlement framework.